FEI announces details of banned substance cases

Lausanne (SUI), 28 July 2016 – The FEI has announced an adverse analytical finding involving a prohibited substance, and Final Decisions in two separate cases. Samples taken at the CPEDI3* in Somma Lombardo (ITA) on 19 June 2016 from the horse Dendros (FEI ID 103IT53), ridden to six place by Matthias Klausener (FEI ID 10057973), have returned positive for the banned substance Demecolcine. Demecolcine, a rheumatic treatment and chemotherapy, is a banned substance under the FEI’s Equine Anti-Doping and Controlled Medication Regulations (EADCMRs). The athlete has been provisionally suspended from the date of notification (27 July 2016). The horse has also been provisionally suspended for a two-month period.

Further details on this case can be found here.

Separately, the FEI Tribunal has issued Final Decisions in two prohibited substance cases. The FEI Tribunal has imposed a two-year suspension on the Uruguayan athlete Fernanda Villar (FEI ID 10062746), effective immediately. Samples taken from the horse LG Muneerah (FEI ID 104TQ89), winner of the CEI2* in Trinidad (URA) on 8 August 2015, returned positive for the prohibited substance Guanabenz, a sedative with analgesic effects. Guanabenz is a banned substance under the FEI EADCMRs. The period of provisional suspension, which came into effect on 29 September 2015, the date of notification, has been credited against the period of ineligibility, which will run through to 22 June 2017. The athlete is also fined CHF 2,000 and ordered to contribute CHF 1,500 towards the cost of the judicial procedure.

The full Final Decision is available here.  

A two-year suspension has also been imposed on the Iranian athlete Mohammad Davoud Shekofti (FEI ID 10120008). Samples taken from the horse Sir de Diamant (FEI ID 102PH75), which finished fifth and eight at the CSI2* in Tehran (IRI) on 22-25 September 2015, returned positive for the banned substance Stanozol and its metabolite 16 Beta Hydroxy-Stanozol, and the controlled medication substances Flunixin and Dexamethasone. Stanozol is an anabolic steroid. Flunixin is a non-steroidal anti-inflammatory drug (NSAID) and Dexamethasone is a corticosteroid with anti-inflammatory effect. The athlete is suspended with immediate effect. The period of provisional suspension, which came into effect on 16 November 2015, the date of notification, has been credited against the period of ineligibility, which runs through to 15 November 2017. The athlete is also fined CHF 2,000 and ordered to contribute CHF 2,000 towards the cost of the judicial procedure.

The full Final Decision is available here.

Both athletes have 21 days from the date of notification of the Final Decision (27 July 2016) to appeal these decisions to the Court of Arbitration for Sport.

FEI PRESS RELEASE